IMA Clinical Research

Executive Summary

IMA Clinical Research is a US-based clinical research organization (CRO) and site network founded in 2008, operating a flexible network of clinical trial sites and patient outreach centers. The company enables site-based, hybrid, and fully decentralized trials, positioning itself as a patient-centric partner for sponsors and CROs, with a focus on broad patient access and diversity. As a private company with no disclosed funding or valuation, IMA Clinical Research operates in the competitive CRO market, leveraging its decentralized capabilities to differentiate itself. The company's model aligns with the growing demand for decentralized clinical trials (DCTs), which offer improved patient recruitment, retention, and data collection. However, the lack of public financial data or disclosed partnerships limits visibility into its growth trajectory. IMA's success hinges on its ability to secure contracts with large pharmaceutical sponsors and expand its site network across the US. The company's estimated size is small to mid-sized, competing with larger CROs like IQVIA and PPD, but its niche in patient-centric DCTs could drive adoption. Given the private nature and limited public information, the conviction in near-term performance is moderate.

Upcoming Catalysts (preview)

• 2026Announcement of a major partnership with a top pharmaceutical company for decentralized trial services40% success
• 2026Expansion of site network to new US regions, increasing trial capacity60% success
• 2026Publication of case studies or white papers demonstrating improved patient diversity and recruitment metrics70% success